Please login to the form below

Not currently logged in
Email:
Password:

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

CureVac Pierre KemulaTübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

Kemula will have responsibility for managing CureVac's financial and capital markets activities and joins the company's management board.

Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.

He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.

Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

14th October 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics